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A B S T R A C THepatitis C virus (HCV) is a globally significant blood-borne agent causing liver diseases, and it has infected over
170million peopleworldwide. HCV is a diverse group of RNAviruses currently divided into genotypes 1–7 as well
as subtypes. HCV infection can be treated with antiviral drugs, but the HCV genotype has to be determined for
optimal selection of treatment strategy. The aim of this study was to set up a sequencing-based HCV genotyping
method suitable for the workflow of a diagnostic laboratory. The established method is robust and stable, and it
utilizes a one-step reverse transcription and PCR amplification of the 50 untranslated region (50UTR) and partial
Core region of the HCV genome. Amplification products are sequenced using the standard Sangermethod, and the
genotype is determined by using a freely accessible web-based genotyping tool. The method was validated at the
Helsinki University Hospital Laboratory using 238 previously genotyped serum samples.
 A new one-step RT-PCR method for the amplification of the 50 untranslated region and partial Core region of
hepatitis C virus was established.
 HCV genotype is determined using Sanger sequencing and a freely accessible, easy-to-use web-based
genotyping tool.
 The method is robust, reproducible and suitable for diagnostic laboratory workflow, and it requires no costlyun
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crinstrumentation or specialized sequence analysis skills.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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The HCV genotyping method described here was developed for a diagnostic laboratory workflow,
aiming at a simple and straightforward protocol. A requirement for themethodwas that all genotypes
should be amplified using only one primer pair in a single amplification reaction. The method utilizes
the detailed and objective information provided by nucleotide sequencing, but requires no specific
analysis skills or costly tools to determine the main HCV genotype.
RNA extraction and PCR amplification1) Extract nucleic acids using the automated NucliSENS easyMAG extraction system (bioMérieux,
Marcy-l'Étoile, FR). Use 200ml of serum and Generic 2.0.1 protocol for extraction, and elute nucleic
acids into 25ml of NucliSens Extraction Buffer (BioMerieux). If PCR amplification is not performed
directly after extraction, the nucleic acid preparations can be stored in 70 C.2) For PCR amplification, use SuperScript III One-Step RT-PCR Systemwith Platinum Taq High Fidelity
polymerase (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), where reverse transcription
(RT) and PCR reactions are run in one reaction.3) Set upa25ml PCR reaction containing0.9mMof forward (50 GTCTAGCCATGGCGTTAGTATGAGTG30)
andreverse (50 ACAAGTAAACTCCACCAACGATCTG30)primers,12.5ml of2xreactionmix(Invitrogen),
0.5ml of SS III RT/Platinum Taq HiFi enzyme mix (Invitrogen) and 3ml of nucleic acid template.4) Run the reactions in a standard thermal cycler. In our laboratory the DNA Engine Tetrad12 Peltier
Thermal Cycler (BioRad, Hercules, CA, USA) was used with the following RT-PCR conditions: cDNA
synthesis for 30min at 55 C, RT-enzyme inactivation for 2min at 94 C, 40 cycles of 15 s
denaturation at 94 C, 30 s annealing at 58 C and 1min extension at 68 C, followed by a final
extension for 5min at 68 C and cooling to 4 C.5) The success of amplification can be inspected using gel electrophoresis. In our laboratory 1.8%
agarose gels stained with ethidium bromide, or the fast electrophoresis FlashGel System (Lonza,
Basel, Switzerland) were used. The expected product length is 374 bp.
Sanger sequencing and sequence analysis1) The amplification products should be sequenced in both directions using standard Sanger
sequencing and the amplification primers described above. Our samples were sequenced at the
Institute of Biotechnology, University of Helsinki.2) Inspect the retrieved chromatograms by using a standard program, for example Chromas (http://
technelysium.com.au/wp/chromas/) or 4peaks (http://nucleobytes.com/4peaks/). Copy the high
quality sequence portionwith unambiguous individual peaks for analysis. The forward and reverse
sequences are analysed separately for each sample without making one consensus sequence.
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http://www.ncbi.nlm.nih.gov/projects/genotyping [1]. The tool compares the inserted sequence to
a HCV sequence database and gives a list of best matches with distinct genotype and subtype
information arranged according to scoring points, highest scores indicating the best match.




All samples (N = 238) used in the establishment and validation of this method had been previously
genotyped at the Helsinki University Hospital Laboratory (HUSLAB), Department of Virology and
Immunology, by using the Versant HCV Genotype 2.0 (Siemens Healthcare, Tarrytown, NY, USA) line
probe assay (LiPA). Viral loads were quantified for a proportion of samples using the COBAS1
AmpliPrep/COBAS1 TaqMan1 HCV Quantitative Test version 2.0 (Roche Molecular Diagnostics,
Pleasanton, CA, USA). After initial analysis the samples had been frozen and stored at 20 C.
Selection of primers
For primer design 50UTR, core/E1 and NS5B regionswere selected. For each region 2–4 primer pairs
were designed by aligning and comparing reference sequences within the selected regions and by
selecting sequences which would share maximal homology between different genotypes. The
requirement was that each genotype should be amplified using only one primer pair in a single
amplification reaction. For the design process the Basic Local Alignment Search Tool (BLASTN) 2.2.27+
[2] and Primer-BLAST [3] programs were used. The reference sequences were M62321 (genotype 1a),
D90208 (1b), D14853 (1c), D00944 (2a), D10988 (2b), D50409 (2c), D17763 (3a), D49374 (3b), Y11604
(4a), Y13184 (5a) and Y12083 (6a). Some primer sequences that had been previously published from
our laboratory were utilized as well [4]. All primers (Integrated DNA Technologies, Coralville, IA, USA)
were initially tested at annealing temperatures of 50 C and 55 C, after which the temperatures were
further adjusted at intervals of 3 C starting from the temperature which produced stronger
amplification products for each genotype. All primer sequences and annealing temperatures for each
primer pair, as well as success of amplification are presented in Table 1.
PCR optimization
For initial primer testing, a set of eight samples representing all main genotypes and most common
subtypes (1a,1b, 2a, 2b, 3a, 4, 5a and6)wasused. Outof all primers, only 50UTR1Fand50UTR1Rwere able
to amplify all samples in our testing set, and were thus selected for further optimization. Reaction
conditions were adjusted for the following parameters: annealing temperature, primer concentration,
magnesiumconcentration, amountof template andnumberof amplificationcycles.Using theoptimized
PCR conditions presented above, a total of 238 serum samples were amplified (Table 2). Strong
amplificationproductswere generallyobtained fromsampleswhose viral loadswere over 10 000 IU/ml.
Distinctbutweakerproductswereobtained fromsampleswhose knownviral loadswere1020–9810 IU/
ml. Samples which remained negative in gel had viral loads of 52–2550 IU/ml. Amplification with the
established method did not directly correlate with viral load. This may be due to long storage time and
multiple freeze-thaw cycles of the samples. The sensitivity of the method was found adequate for
genotyping of patient samples, whose viral loads are generally between 104–107 IU/mL.
Sequencing
Altogether 201 amplification products were sequenced (Table 2), including nine samples where no
amplification product was observed in agarose gel. In total, 197 genotyping results were obtained,
Table 2
Success of HCV genotyping using the established method.
LiPA genotypea 1 2 3 4 5 6 1a/4 2b/1a Unknownb NCc Total
Samples amplified 78 37 100 13 4 1 2 1 1 1 238
Product in gel 71 32 96 12 4 1 2 1 0 0 219
No product in gel 7 5 4 1 0 0 0 0 1 1 19
Samples sequenced 64 30 92 7 4 1 1 1 1 0 201
Retrieved genotype results 64 28 91 7 4 1 1 1 0 0 197
a Versant HCV Genotype 2.0 (Siemens Healthcare, Tarrytown, NY, USA) line probe assay.
b Genotype could not be identified using the LiPA method.
c Negative control, a patient sample tested negative for HCV.
Table 1
Primers tested for PCR amplification of different HCV genotypes. Nucleotide numbering and product length are according to
HCV 1a isolate H77 (GenBank accession number AF009606). Primers amplifying several genotypes are highlighted in bold.





5’UTR 1 F 77 102 GTCTAGCCATGGCGTTAGTATGAGTG 374 58 C 1a, 1b, 2a, 2b,
5’UTR 1 R 450 426 ACAAGTAAACTCCACCAACGATCTG 3a, 4, 5a, 6
5’UTR 2 F 74 91 AGCGTCTAGCCATGGCGT 265 50/55 C* Several short
5’UTR 2 R 338 321 GCACGGTCTACGAGACCT products
5’UTR 3 F 73 90 AAGCGTCTAGCCATGGCG 267 50/55 C* Several short
5’UTR 3 R 339 322 TGCACGGTCTACGAGACC products
5’UTR 4 F 143 159 GTGGTCTGCGGAACCGG 174 50/55 C* No amplification
5’UTR 4 R 316 299 GGGCACTCGCAAGCACCC products
Core/E1 1 F 733 750 CCGACCTCATGGGGTACA 589 55 C 2a, 3a
Core/E1 1 R 1321 1299 GACCAGTTCATCATCATATCCCA
Core/E1 2 F 841 859 GGAACCTTCCTGGTTGCTC 481 50/55 C* No amplification
Core/E1 2 R 1321 1299 GACCAGTTCATCATCATATCCCA products
Core/E1 3 F 842 869 GAACCTTCCTGGTTGCTCTTTCTCTATC 487 47 C 1a, 1b, 2a, 3a,
Core/E1 3 R 1328 1306 CGTAGGGGACCAGTTCATCATCA 4, 6
NS5B 1 F 7952 7970 CCACATCAACTCCGTGTGG 684 50/55 C* 2a, (2b, 1a)
NS5B 1 R 8635 8616 CTGGTCATAGCCTCCGTGAA
NS5B 2 F 8010 8031 ACCATCATGGCCAAGAACGAGG 632 50/55 C* No amplification
NS5B 2 R 8641 8620 GAGTACCTGGTCATAGCCTCCG products
NS5B 3 F 8010 8031 ACCATCATGGCCAAGAACGAGG 698 50 C 2a, 2b, 3a, 4,
NS5B 3 R 8707 8682 TTGGAGGAGCATGATGTTATAAGCTC (1b)
NS5B 4 F 7953 7976 CACATCAACTCCGTGTGGAAAGAC 755 52 C 1a, 1b, 2a, 4,
NS5B 4 R 8707 8682 TTGGAGGAGCATGATGTTATAAGCTC (6)
Genotypes which were inconsistently amplified are given in brackets.
* Primers were tested using two different annealing temperatures which performed equally.
E. Virtanen et al. /MethodsX 5 (2018) 414–418 417including five gel-negative samples. The four samples where no genotyping result was obtained were
all gel-negative amplification reactions. The length of the obtained sequences was approximately
300 bp for the majority of samples. The sequence based genotyping results were consistent with LiPA
results except for three samples, where a different result at the main genotype level was obtained. For
one sample the LiPA method yielded an equivocal result of genotype 2 while sequences in both
directions matched genotype 3a. For the second sample both sequences indicated genotype 1b
whereas LiPA identified genotype 5a. For the third equivocal sample no amplification product was
seen in gel, and only a short reverse sequence indicating genotype 2k was derived, while the LiPA
result indicated genotype 1. For two additional samples, two alternative genotypes were reported
from LiPA analysis: 2b/1a and 1a/4. The forward and reverse sequences from both of these samples
clearly matched genotype 1.
418 E. Virtanen et al. /MethodsX 5 (2018) 414–418Conclusions
50UTR sequences suit well for main HCV genotype determination and in certain cases for subtype
determination as well. However, because of its conserved nature, the 50UTR cannot be applied to
reliably distinguish genotype 1 subtypes. The established genotyping method is straightforward and
robust, fits well to the diagnostic laboratory workflow, and does not require costly instrumentation or
specialized sequence analysis skills.
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